Thu, February 16, 2023
Wed, February 15, 2023
Tue, February 14, 2023

Judah Frommer Maintained (SRPT) at Hold with Increased Target to $137 on, Feb 15th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-137-on-feb-15th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Judah Frommer of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $114 to $137 on, Feb 15th, 2023.

Judah has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 0 agree with Judah's Rating of Hold.



These are the ratings of the 7 analyists that currently disagree with Judah


  • Joseph Schwartz of "SVB Leerink" Reiterated at Buy and Held Target at $160 on, Friday, January 20th, 2023
  • Gil Blum of "Needham" Maintained at Strong Buy with Increased Target to $160 on, Tuesday, January 10th, 2023
  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $160 on, Thursday, December 22nd, 2022
  • Colin Bristow of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $158 on, Friday, December 16th, 2022
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $138 on, Tuesday, November 29th, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $190 on, Thursday, November 3rd, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $171 on, Thursday, November 3rd, 2022

Publication Contributing Sources